Investigation of treatment volume versus circulating blood volume during Rheocarna treatment

Abstract

AbstractIntroductionRheocarna's therapeutic effect is associated with fibrinogen (Fib) and low‐density lipoprotein cholesterol (LDL‐C) adsorptive removal. This study aimed to retrospectively investigate the association between treatment volume (TV) and circulating blood volume (CBV) and the Fib removal rate (Fib‐RR) and LDL‐C‐RR.MethodsCBV and TV/CBV, cut‐off value (CO value), and area under the receiver operating characteristic (ROC) curve (AUC) were calculated. The Fib‐RR and LDL‐C‐RR at the midterm and end of treatment were compared. The groups were further categorized into three groups with TV/CBV lower than or higher than the CO value at the midterm and end (midterm/end; Group L: lower than/lower than CO; Group L/H: lower than/higher than CO; Group H: higher than/higher than CO), and the Fib‐RR and LDL‐RR of each group at the midterm and end were compared.ResultsROC analysis revealed a TV of 1.480 times the BV as CO value, which showed a maximum Youden index predicting a Fib‐RR of 20% (AUC: 0.828). Among the three groups, Group L and Group L/H demonstrated significantly higher Fib‐RR and LDL‐C‐RR at the end of the study than in the midterm, while Group H exhibited no difference.ConclusionThe results reveal that a treatment volume of 1.5 times the circulating blood volume is a sufficient solute removal capacity in the Rheocarna‐enabled cases.